Rita Axelrod

Thomas Jefferson University Hospital

Papers

1

Total Citations

13

H-Index

1

About

Dr. Rita Axelrod is a leading surgical oncologist whose research focuses on the intersection of immunotherapy and head and neck cancer surgery. Her key contributions center on understanding how preoperative immune checkpoint inhibition—specifically targeting PD-1 and PD-L1 pathways—affects surgical outcomes for patients with head and neck squamous cell carcinoma (HNSCC). In her landmark 2023 study, Dr. Axelrod provided critical evidence comparing complication rates between patients who received neoadjuvant immunotherapy prior to surgery and those who underwent surgery alone. This work, which has already garnered 13 citations, addresses a significant gap in the literature and has direct implications for optimizing treatment sequencing in HNSCC. Her research is particularly notable for its focus on balancing the promise of immunotherapy with the practical realities of surgical safety. By systematically evaluating postoperative outcomes, Dr. Axelrod has helped establish a foundation for integrating immune checkpoint inhibitors into the perioperative setting. Her work is essential reading for clinicians and researchers seeking to improve outcomes in head and neck cancer through innovative, evidence-based approaches that bridge oncology and surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
Effect of preoperative programmed death‐1 or programmed death ligand‐1 immune check point inhibition on complications after surgery for primary head and neck cancer
13 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Thomas Jefferson University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago